Oerth Bio
Company

Last deal

$55M

Amount

Corporate Round

Stage

27.02.2020

Date

1

all rounds

$55M

Total amount

date founded

Financing round

General

About Company
Oerth Bio is an agriculture-focused biotech firm revolutionizing farming for the future.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2019

Number of employees

Company Type

For Profit

Last funding type

Corporate Round

IPO status

Private

Description

Leveraging Arvinas' innovative PROTAC protein degrader technology, Oerth Bio develops targeted protein degraders specifically designed for agricultural applications. Their groundbreaking approach has the potential to transform farming practices, enabling more efficient and sustainable crop production. Additionally, Oerth Bio is utilizing this technology to develop new human therapeutics for patients suffering from cardiovascular, oncological, and gynecological diseases. With their pioneering solutions, Oerth Bio is reshaping the future of agriculture and healthcare, paving the way for a more prosperous and sustainable world.
Contacts

Social url

Similar Companies
1000
AgGenetics

AgGenetics

AgGenetics helps farmers produce more protein with fewer resources.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Murfreesboro, TN, USA

total rounds

3

total raised

$590K
ORF Genetics

ORF Genetics

ORF Genetics is an innovative company that produces recombinant proteins using its Orfeus™ expression system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Manufacturing, Food and Beverage

Location

Kópavogur, Iceland

total rounds

10

total raised

$2.38M
MNPHARM

MNPHARM

MNPHARM uses molecular farming to produce affordable recombinant proteins for regenerative medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

White Bear Lake, MN, USA

total rounds

4

total raised

$400K
GenoFocus

GenoFocus

GenoFocus is a high-throughput protein evolution company that provides enzyme solutions for various industries.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Daejeon, Jeong-dong, Daejeon, South Korea

total rounds

1

Financials

Funding Rounds
1
1

Number of Funding Rounds

$55M

Money Raised

Their latest funding was raised on 27.02.2020. Their latest investor Bayer. Their latest round Corporate Round

Date 
Funding Round 
Investors 
Money Raised 
Lead 
27.02.2020
2
$55M
Co-Investors
Investors
2
0

Number of lead investors

2

Number of investors

Investor 
Lead 
Round 
Partners 
No
Corporate Round
No
Corporate Round
Bayer

Bayer

Bayer focuses on healthcare, nutrition, and crop science.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Leverkusen, Germany

total rounds

2

total raised

$3.72B

count Of Investments

26

count Of Exists

3
Arvinas

Arvinas

Arvinas is a pharmaceutical company that develops novel therapeutics to treat a variety of diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

New Haven, CT, USA

total rounds

4

total raised

$461.6M

count Of Investments

1

People

Founders
1
John W. Dombrosky
John W. Dombrosky

John W. Dombrosky

Strategic general manager with experience driving business results. Fosters strong relationships, persuades with energy, and operates confidently in complex, global structures. Experience spans biotechnology, chemical, information, software, and transportation industries. The pursuit of lifelong learning brings fresh interest and energy into each day.

current job

Oerth Bio
Oerth Bio

John W. Dombrosky

Employee Profiles
1
John W. Dombrosky

John W. Dombrosky

Founder & CEO

Activity

Recent News
0